ERBB2 and breast carcinoma: uPAR was also knocked down in combination with the RNAi of uPA, HER2 or MMP9 or combined with Trastuzumab in different breast cancer cell lines and in in vivo studies resulting in reduced cell migration, invasion, angiogenesis or proliferation [31–33].